(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 October 2009 (15.10.2009)

PCT

(10) International Publication Number
WO 2009/125424 A3

(51) International Patent Classification:
C07K 14/605 (2006.01) *A61K 38/26* (2006.01)

(21) International Application Number:
PCT/IN2008/000831

(22) International Filing Date:
10 December 2008 (10.12.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2420/MUM/2007 11 December 2007 (11.12.2007) IN
1696/MUM/2008 11 August 2008 (11.08.2008) IN

(71) Applicant *(for all designated States except US)*: **CADILA HEALTHCARE LIMITED** [IN/IN]; Zydus Tower, Satellite Cross Roads, Ahmedabad 380 015, Gujarat (IN).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BAHEKAR, Rajesh, H.** [IN/IN]; Cadila Healthcare Limited, Zydus Tower, Satellite Cross Roads, Ahmedadbad 380 015, Gujarat (IN). **JAIN, Mukul, R** [IN/IN]; Cadila Healthcare Limited, Zydus Tower, Satellite Cross Roads, Ahmedadbad 380 015, Gujarat (IN). **PATEL, Pankaj, Ramanbhai** [IN/IN]; Cadila Healthcare Limited, Zydus Tower, Satellite Cross Roads, Ahmedadbad 380 015, Gujarat (IN).

(74) Agent: **SUBRAMANIAM, Hariharan**; Subramaniam, Nataraj & Associates, E-556, Greater Kailash-II, New Delhi 110 048 (IN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
23 December 2009

(54) Title: PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP-1 AGONISTIC ACTIVITIES

Figure 1: *In vitro* Human Glucagon receptor antagonistic activity and GLP-1 receptor agonistic activity with **Seq. ID. No.5.**




Figure A showed % inhibition of glucagon peptide activity in human glucagon receptor overexpressed in CHO cell lines, incubated with different concentration of **Seq. ID 5**; **Figure B** showed % activity (cAMP release) wrt Ex-4, with **Seq. ID 5**, in human GLP-1 receptor overexpressed in CHO cell lines.

(57) Abstract: The present invention provides novel peptidomimetics, of formula (I), which primarily act as glucose dependent insulin secretagogues. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-I receptor agonistic activity.

WO 2009/125424 A3